netaxan
sifi s.p.a. - deksametazonas/netilmicinas - akių lašai (tirpalas) - 1 mg/3 mg/ml - dexamethasone and antiinfectives
netaxan
sifi s.p.a. - deksametazonas/netilmicinas - akių lašai (tirpalas vienadozėje talpyklėje) - 1 mg/3 mg/ml - dexamethasone and antiinfectives
orlixon
lex ano, uab - deksametazono natrio fosfatas - injekcinis ar infuzinis tirpalas - 4 mg/ml - dexamethasone
maxidrol
lex ano, uab - deksametazonas/neomicino sulfatas/polimiksino b sulfatas - akių lašai (suspensija) - 1 mg/3500 tv/6000 tv/ml - dexamethasone and antiinfectives
maxidrol
lex ano, uab - deksametazonas/neomicino sulfatas/polimiksino b sulfatas - akių tepalas - 1 mg/3500 tv/6000 tv/g - dexamethasone and antiinfectives
dexametazona rompharm
tojaris projektai, uab - deksametazono natrio fosfatas - injekcinis ar infuzinis tirpalas - 4 mg/ml - dexamethasone
maxidrol
ideal trade links, uab - deksametazonas/neomicino sulfatas/polimiksino b sulfatas - akių tepalas - 1 mg/3500 tv/6000 tv/g - dexamethasone and antiinfectives
maxitrol
lex ano, uab - deksametazonas/neomicino sulfatas/polimiksino b sulfatas - akių lašai (suspensija) - 1 mg/3500 tv/6000 tv/ml - dexamethasone and antiinfectives
sarclisa
sanofi winthrop industrie - isatuximab - daugybinė mieloma - antinavikiniai vaistai - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
nexpovio
stemline therapeutics b.v. - selinexor - daugybinė mieloma - antinavikiniai vaistai - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.